Towards new mechanisms: An update on therapeutics for treatment-resistant major depressive disorder

Molecular Psychiatry

Volumn 20, Issue 10, 2015, Pages 1142-1150

  Papakostas, G I ^a   Ionescu, D F ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKS 5461; ANTIDEPRESSANT AGENT; AVP 786; CELECOXIB; CP 601 927; DEXMECAMYLAMINE; DEXTROMETHORPHAN; EDIVOXETINE; INFLIXIMAB; KETAMINE; LANICEMINE; LEVO METHYLFOLATE; LISDEXAMFETAMINE; MECAMYLAMINE; MEMANTINE; METABOTROPIC RECEPTOR; MK 0657; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NITROUS OXIDE; ORG 263576; PRAMIPEXOLE; RAPASTINEL; RILUZOLE; S ADENOSYLMETHIONINE; SCOPOLAMINE; SEROTONIN UPTAKE INHIBITOR; TESTOSTERONE; UNCLASSIFIED DRUG; VORTIOXETINE; AMINO ACID RECEPTOR AFFECTING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; NARCOTIC ANALGESIC AGENT;

ALTERNATIVE MEDICINE; ANTIDEPRESSANT ACTIVITY; CLINICAL ASSESSMENT; CLINICAL OBSERVATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EXERCISE; EXPERIMENTAL THERAPY; HUMAN; META ANALYSIS (TOPIC); MONOTHERAPY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLACEBO EFFECT; POPULATION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESISTANT DEPRESSION; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT;

ANALGESICS, OPIOID; CHOLINERGIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; EXCITATORY AMINO ACID AGENTS; HUMANS;

EID: 84942552433     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2015.92     Document Type: Review

References (108)

1. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013; 382: 1575-1586.
2. Mrazek DA, Hornberger JC, Altar CA, Degtiar I. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013. Psychiatr Serv 2014; 65: 977-987.
3. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR D report. Am J Psychiatry 2006; 163: 1905-1917.
4. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003; 53: 649-659.
5. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997; 58: 23-29.
6. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-Analysis of placebo-controlled randomized trials. Am J Psychiatry 2009; 166: 980-991.
7. Papakostas GI. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry 2009; 70: 16-25.
8. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47: 351-354.
9. Sos P, Klirova M, Novak T, Kohutova B, Horacek J, Palenicek T. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression. Neuro Endocrinol Lett 2013; 34: 287-293.
10. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA et al. A randomized trial of an N-methyl-D-Aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856-864.
11. McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. A systematic review and meta-Analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med 2014; 45: 693-704, 1-12.
12. Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 2013; 170: 1134-1142.
13. Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Slonena EE, Vande Voort JL et al. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. J Clin Psychiatry 2014; 75: e932-e938.
14. Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Zarate CA Jr. A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. Bipolar Disord 2014; 17: 438-443.
15. DiazGranados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-Aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 2010; 71: 1605-1611.
16. Price RB, Nock MK, Charney DS, Mathew SJ. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 2009; 66: 522-526.
17. Lally N, Nugent AC, Luckenbaugh DA, Ameli R, Roiser JP, Zarate CA. Antianhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry 2014; 4: e469.
18. Wan LB, Levitch CF, Perez AM, Brallier JW, Iosifescu DV, Chang LC et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry 2014; 76: 247-252.
19. Lapidus KA, Levitch CF, Perez AM, Brallier JW, Parides MK, Soleimani L et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry 2014; 76: 970-976.
20. Zunszain PA, Horowitz MA, Cattaneo A, Lupi MM, Pariante CM. Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties. Mol Psychiatry 2013; 18: 1236-1241.
21. Sanacora G, Smith MA, Pathak S, Su HL, Boeijinga PH, McCarthy DJ et al. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry 2013; 19: 978-985.
22. Zarate CA Jr, Mathews D, Ibrahim L, Chaves JF, Marquardt C, Ukoh I et al. A randomized trial of a low-trapping nonselective N-methyl-D-Aspartate channel blocker in major depression. Biol Psychiatry 2013; 74: 257-264.
23. Zarate CA Jr., Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006; 163: 153-155.
24. Smith EG, Deligiannidis KM, Ulbricht CM, Landolin CS, Patel JK, Rothschild AJ. Antidepressant augmentation using the N-methyl-D-Aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2013; 74: 966-973.
25. Wang SJ, Wang KY, Wang WC. Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes). Neuroscience 2004; 125: 191-201.
26. Zarate CA Jr, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004; 161: 171-174.
27. Sanacora G, Kendell SF, Levin Y, Simen AA, Fenton LR, Coric V et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 2007; 61: 822-825.
28. Ibrahim L, Diazgranados N, Franco-Chaves J, Brutsche N, Henter ID, Kronstein P et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 2012; 37: 1526-1533.
29. Niciu MJ, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, Ballard ED et al. Riluzole likely lacks antidepressant efficacy in ketamine non-responders. J Psychiatr Res 2014; 58: 197-199.
30. Ibrahim L, Diaz Granados N, Jolkovsky L, Brutsche N, Luckenbaugh DA, Herring WJ et al. A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol 2012; 32: 551-557.
31. Nagele P, Duma A, Kopec M, Gebara MA, Parsoei A, Walker M et al. Nitrous oxide for treatment-resistant major depression proof-of-concept trial. Biol Psychiatry 2014; 78: 10-18.
32. Burgdorf J, Zhang XL, Nicholson KL, Balster RL, Leander JD, Stanton PK et al. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology 2013; 38: 729-742.
33. Moskal JR, Burch R, Burgdorf JS, Kroes RA, Stanton PK, Disterhoft JF et al. GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists. Expert Opin Investig Drugs 2014; 23: 243-254.
34. Pope LE, Khalil MH, Berg JE, Stiles M, Yakatan GJ, Sellers EM. Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers. J Clin Pharmacol 2004; 44: 1132-1142.
35. Lauterbach EC. An extension of hypotheses regarding rapid-Acting, treatmentrefractory, and conventional antidepressant activity of dextromethorphan and dextrorphan. Med Hypotheses 2012; 78: 693-702.
36. Zarate CA Jr, Manji HK. The role of AMPA receptor modulation in the treatment of neuropsychiatric diseases. Exp Neurol 2008; 211: 7-10.
37. Nations KR, Bursi R, Dogterom P, Ereshefsky L, Gertsik L, Mant T et al. Maximum tolerated dose evaluation of the AMPA modulator Org 26576 in healthy volunteers and depressed patients: a summary and method analysis of bridging research in support of phase II dose selection. Drugs R&D 2012; 12: 127-139.
38. Nations KR, Dogterom P, Bursi R, Schipper J, Greenwald S, Zraket D et al. Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial. J Psychopharmacol 2012; 26: 1525-1539.
39. Pilc A, Chaki S, Nowak G, Witkin JM. Mood disorders: regulation by metabotropic glutamate receptors. Biochem Pharmacol 2008; 75: 997-1006.
40. Quiroz JA, Tamburri P, Deptula D, Banken L, Beyer U, Fontoura P et al. The efficacy and safety of basimglurant as adjunctive therapy in major depression; a randomised, double-blind, placebo-controlled study. Eur Neuropsychopharmacol 2014; 24: S468.
41. Janowsky DS, Overstreet DH. The Role of Acetylcholine Mechanisms in Mood Disorders. Raven Press: New York, NY, USA, 1995.
42. Furey ML, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry 2006; 63: 1121-1129.
43. Jaffe RJ, Novakovic V, Peselow ED. Scopolamine as an antidepressant: a systematic review. Clin Neuropharmacol 2013; 36: 24-26.
44. Drevets WC, Furey ML. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry 2010; 67: 432-438.
45. Ellis JS, Zarate CA Jr, Luckenbaugh DA, Furey ML. Antidepressant treatment history as a predictor of response to scopolamine: clinical implications. J Affect Disord 2014; 162: 39-42.
46. Furey ML, Khanna A, Hoffman EM, Drevets WC. Scopolamine produces larger antidepressant and antianxiety effects in women than in men. Neuropsychopharmacology 2010; 35: 2479-2488.
47. Shytle RD, Silver AA, Lukas RJ, Newman MB, Sheehan DV, Sanberg PR. Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry 2002; 7: 525-535.
48. Lindsley CW. (S)-(+)-mecamylamine (TC-5214): a neuronal nicotinic receptor modulator enters phase III trials as an adjunct treatment for major depressive disorder (MDD). ACS Chem Neurosci 2010; 1: 530-531.
49. Dunbar G, Kuchibhatla R, Kumar R. Mecamylamine as an Augmentation Treatment for Depressed Patients who were Non-responders to Citalopram. Poster presented at 19th ECNP Congress; 16-20 September 2006; Paris, France.
50. Vieta E, Thase ME, Naber D, D'Souza B, Rancans E, Lepola U et al. Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressant. Eur Neuropsychopharmacol 2014; 24: 564-574.
51. Iovieno N, Papakostas GI. Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-Analysis. J Clin Psychiatry 2012; 73: 1300-1306.
52. Iovieno N, Papakostas GI. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/ combination strategies in treatment partial responders/nonresponders with major depressive disorder? J Clin Psychiatry 2012; 73: 676-683.
53. Mineur YS, Einstein EB, Seymour PA, Coe JW, O'Neill B T, Rollema H et al. Alpha4beta2 nicotinic acetylcholine receptor partial agonists with low intrinsic efficacy have antidepressant-like properties. Behav Pharmacol 2011; 22: 291-299.
54. Fava M, Ramey T, Pickering E, Kinrys G, Boyer S, Altstiel L. A randomized, doubleblind, placebo-controlled phase 2 study of the augmentation of a nicotinic acetylcholine receptor partial agonist in depression: is there a relationship to leptin levels?. J Clin Psychopharmacol 2015; 35: 51-56.
55. Berrocoso E, Sanchez-Blazquez P, Garzon J, Mico JA. Opiates as antidepressants. Curr Pharmaceut Des 2009; 15: 1612-1622.
56. Garriock HA, Tanowitz M, Kraft JB, Dang VC, Peters EJ, Jenkins GD et al. Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder. Am J Psychiatry 2010; 167: 565-573.
57. Ehrich E, Turncliff R, Du Y, Leigh-Pemberton R, Fernandez E, Jones R et al. Evaluation of opioid modulation in major depressive disorder. Neuropsychopharmacology 2014; 40: 1448-1455.
58. Schatzberg AF, Blier P, Culpepper L, Jain R, Papakostas GI, Thase ME. An overview of vortioxetine. J Clin Psychiatry 2014; 75: 1411-1418.
59. Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data. Pharmacol Ther 2014; 145: 43-57.
60. Pearce EF, Murphy JA. Vortioxetine for the treatment of depression. Ann Pharmacother 2014; 48: 758-765.
61. Montgomery SA, Nielsen RZ, Poulsen LH, Haggstrom L. A randomised, doubleblind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol 2014; 29: 470-482.
62. Trivedi MH, Cutler AJ, Richards C, Lasser R, Geibel BB, Gao J et al. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram. J Clin Psychiatry 2013; 74: 802-809.
63. Ionescu DF, Niciu MJ, Richards EM, Zarate CA. Pharmacologic treatment of dimensional anxious depression: a review. Prim Care Companion CNS Disord 2014; 16: e1-e13.
64. Shire Press Release, 2/6/13. http://www. shire. com/shireplc/en/investors/inves torsnews/irshirenews?id = 921.
65. Ball S, Dellva MA, D'Souza DN, Marangell LB, Russell JM, Goldberger C. A doubleblind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment. J Affect Disord 2014; 167: 215-223.
66. Eli Lilly Press Release, 12/3/13. https://investor. lilly. com/releasedetail. cfm?relea seid = 811751.
67. Piercey MF. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol 1998; 21: 141-151.
68. Cusin C, Iovieno N, Iosifescu DV, Nierenberg AA, Fava M, Rush AJ et al. A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. J Clin Psychiatry 2013; 74: e636-e641.
69. Franco-Chaves JA, Mateus CF, Luckenbaugh DA, Martinez PE, Mallinger AG, Zarate CA Jr. Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: a double-blind, randomized pilot study. J Affect Disord 2013; 149: 319-325.
70. Papakostas GI, Shelton RC, Zajecka JM, Etemad B, Rickels K, Clain A et al. Lmethylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry 2012; 169: 1267-1274.
71. Papakostas GI, Shelton RC, Zajecka JM, Bottiglieri T, Roffman J, Cassiello C et al. Effect of adjunctive L-methylfolate 15mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial. J Clin Psychiatry 2014; 75: 855-863.
72. Alpert JE, Papakostas G, Mischoulon D, Worthington JJ 3rd, Petersen T, Mahal Y et al. S-Adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J Clin Psychopharmacol 2004; 24: 661-664.
73. Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M. S-Adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry 2010; 167: 942-948.
74. Trivedi MH, Greer TL, Church TS, Carmody TJ, Grannemann BD, Galper DI et al. Exercise as an augmentation treatment for nonremitted major depressive disorder: a randomized, parallel dose comparison. J Clin Psychiatry 2011; 72: 677-684.
75. Sargin D, Friedrichs H, El-Kordi A, Ehrenreich H. Erythropoietin as neuroprotective and neuroregenerative treatment strategy: comprehensive overview of 12 years of preclinical and clinical research. Best Pract Res Clin Anaesthesiol 2010; 24: 573-594.
76. Siren AL, Fasshauer T, Bartels C, Ehrenreich H. Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics 2009; 6: 108-127.
77. Papakostas GI. Cognitive symptoms in patients with major depressive disorder and their implications for clinical practice. J Clin Psychiatry 2014; 75: 8-14.
78. Miskowiak KW, Vinberg M, Christensen EM, Bukh JD, Harmer CJ, Ehrenreich H et al. Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial. Neuropsychopharmacology 2014; 39: 1399-1408.
79. Pope HG Jr, Cohane GH, Kanayama G, Siegel AJ, Hudson JI. Testosterone gel supplementation for men with refractory depression: a randomized, placebocontrolled trial. Am J Psychiatry 2003; 160: 105-111.
80. Orengo CA, Fullerton L, Kunik ME. Safety and efficacy of testosterone gel 1% augmentation in depressed men with partial response to antidepressant therapy. J Geriatr Psychiatry Neurol 2005; 18: 20-24.
81. Pope HG Jr., Amiaz R, Brennan BP, Orr G, Weiser M, Kelly JF et al. Parallel-group placebo-controlled trial of testosterone gel in men with major depressive disorder displaying an incomplete response to standard antidepressant treatment. J Clin Psychopharmacol 2010; 30: 126-134.
82. Rosenblat JD, Cha DS, Mansur RB, McIntyre RS. Inflamed moods: a review of the interactions between inflammation and mood disorders. Progr Neuropsychopharmacol Biol Psychiatry 2014; 53: 23-34.
83. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013; 70: 31-41.
84. Kohler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-Analysis of randomized clinical trials. JAMA Psychiatry 2014; 71: 1381-1391.
85. Na KS, Lee KJ, Lee JS, Cho YS, Jung HY. Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-Analysis. Progr Neuropsychopharmacol Biol Psychiatry 2014; 48: 79-85.
86. Faridhosseini F, Sadeghi R, Farid L, Pourgholami M. Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and metaanalysis of randomized placebo-controlled trials. Hum Psychopharmacol 2014; 29: 216-223.
87. Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry 1999; 156: 675-682.
88. George MS, Taylor JJ, Short B. Treating the depressions with superficial brain stimulation methods. Handb Clin Neurol 2013; 116: 399-413.
89. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron 2002; 34: 13-25.
90. Barker AT, Jalinous R, Freeston IL. Non-invasive magnetic stimulation of human motor cortex. Lancet 1985; 1: 1106-1107.
91. Roth Y, Amir A, Levkovitz Y, Zangen A. Three-dimensional distribution of the electric field induced in the brain by transcranial magnetic stimulation using figure-8 and deep H-coils. J Clin Neurophysiol 2007; 24: 31-38.
92. Allan CL, Herrmann LL, Ebmeier KP. Transcranial magnetic stimulation in the management of mood disorders. Neuropsychobiology 2011; 64: 163-169.
93. Gaynes BN, Lloyd SW, Lux L, Gartlehner G, Hansen RA, Brode S et al. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-Analysis. J Clin Psychiatry 2014; 75: 477-489.
94. O'Reardon JP, Solvason HB, Janicak PG, Sampson S, Isenberg KE, Nahas Z et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry 2007; 62: 1208-1216.
95. Micallef-Trigona B. Comparing the effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy in the treatment of depression: a systematic review and meta-Analysis. Depress Res Treat 2014; 2014: 135049.
96. Brunelin J, Jalenques I, Trojak B, Attal J, Szekely D, Gay A et al. The efficacy and safety of low frequency repetitive transcranial magnetic stimulation for treatment-resistant depression: the results from a large multicenter French RCT. Brain Stimul 2014; 7: 855-863.
97. Bersani FS, Minichino A, Enticott PG, Mazzarini L, Khan N, Antonacci G et al. Deep transcranial magnetic stimulation as a treatment for psychiatric disorders: a comprehensive review. Eur Psychiatry 2013; 28: 30-39.
98. Harel EV, Rabany L, Deutsch L, Bloch Y, Zangen A, Levkovitz Y. H-coil repetitive transcranial magnetic stimulation for treatment resistant major depressive disorder: an 18-week continuation safety and feasibility study. World J Biol Psychiatry 2014; 15: 298-306.
99. Levkovitz Y, Isserles M, Padberg F, Lisanby SH, Bystritsky A, Xia G et al. Safety and efficacy of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. World Psychiatry 2015; 14: 64-73.
100. Kamijima K, Higuchi T, Ishigooka J, Ohmori T, Ozaki N, Kanba S et al. Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study). J Affect Disord 2013; 151: 899-905.
101. Papakostas GI, Ostergaard S, Iovieno N. The nature of placebo response in clinical studies of major depressive disorders. J Clin Psychiatry 2015; 76: 456-466.
102. Papakostas GI, Petersen TJ, Green C, Iosifescu DV, Yeung AS, Nierenberg AA et al. A description of next-step switching versus augmentation practices for outpatients with treatment-resistant major depressive disorder enrolled in an academic specialty clinic. Ann Clin Psychiatry 2005; 17: 161-165.
103. Petersen T, Papakostas GI, Posternak MA, Kant A, Guyker WM, Iosifescu DV et al. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Ppsychopharmacol 2005; 25: 336-341.
104. Papakostas GI, Ionescu DF. Updates and trends in the treatment of major depressive disorder. J Clin Psychiatry 2014; 75: 1419-1421.
105. Rohan ML, Yamamoto RT, Ravichandran CT, Cayetano KR, Morales OG, Olson DP et al. Rapid mood-elevating effects of low field magnetic stimulation in depression. Biol Psychiatry 2014; 76: 186-193.
106. Carr GV, Bangasser DA, Bethea T, Young M, Valentino RJ, Lucki I. Antidepressantlike effects of kappa-opioid receptor antagonists in Wistar Kyoto rats. Neuropsychopharmacology 2010; 35: 752-763.
107. Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens WC Jr et al. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 2003; 305: 323-330.
108. Rorick-Kehn LM, Witkin JM, Statnick MA, Eberle EL, McKinzie JH, Kahl SD et al. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacology 2014; 77: 131-144.